Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study)

被引：0
|
作者：
Segal, N. H. [1 ]
Reidy-Lagunes, D. [1 ]
Capanu, M. [1 ]
Kemeny, N. [1 ]
Chung, K. [1 ]
Kelsen, D. [1 ]
Hollywood, E. [1 ]
Goodman-Davis, N. [1 ]
Saltz, L. B. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4087
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study
    Saltz, Leonard B.
    Lenz, Heinz-Josef
    Kindler, Hedy L.
    Hochster, Howard S.
    Wadler, Scott
    Hoff, Paulo M.
    Kemeny, Nancy E.
    Hollywood, Ellen M.
    Gonen, Mithat
    Quinones, Marcus
    Morse, Meroe
    Chen, Helen X.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) : 4557 - 4561
  • [2] Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer.
    Saltz, LB
    Lenz, HJ
    Hochster, H
    Wadler, S
    Hoff, P
    Kemeny, N
    Hollywood, E
    Gonen, M
    Wetherbee, S
    Chen, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 248S - 248S
  • [3] Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
    Zhang, W.
    Yang, D.
    Capanu, M.
    Hollywood, E.
    Lue-Yat, M.
    Borucka, E.
    Azuma, M.
    Gordon, M.
    Saltz, L.
    Lenz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Molecular Predictors of Combination Targeted Therapies (Cetuximab, Bevacizumab) in Irinotecan-Refractory Colorectal Cancer (BOND-2 Study)
    Zhang, Wu
    Azuma, Mizutomo
    Lurje, Georg
    Gordon, Michael A.
    Yang, Dongyun
    Pohl, Alexandra
    Ning, Yan
    Bohanes, Pierre
    Gerger, Armin
    Winder, Thomas
    Hollywood, Ellen
    Danenberg, Kathleen D.
    Saltz, Leonard
    Lenz, Heinz-Josef
    ANTICANCER RESEARCH, 2010, 30 (10) : 4209 - 4217
  • [5] Molecular markers associated with response and clinical outcome to cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (BOND2)
    Azuma, M.
    Yang, D.
    Carpanu, M.
    Hollywood, E.
    Lue-Yat, M.
    Zhang, W.
    Danenberg, K. D.
    Danenberg, P. V.
    Saltz, L.
    Lenz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Cetuximab plus FOLFIRI for irinotecan-refractory metastatic colorectal cancer: A retrospective study
    Koo, Dong Hoe
    Lee, Jae-Lyun
    Kim, Tae Won
    Ryu, Min-Hee
    Chang, Heung Moon
    Lee, Sung Sook
    Kim, Min Kyoung
    Sym, Sun Jin
    Lee, Jung Shin
    Kang, Yoon-Koo
    ANNALS OF ONCOLOGY, 2006, 17 : 131 - 131
  • [7] Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial
    Lipsyc-Sharf, Marla
    Ou, Fang-Shu
    Yurgelun, Matthew B.
    Rubinson, Douglas Adam
    Schrag, Deborah
    Dakhil, Shaker R.
    Stella, Philip J.
    Weckstein, Douglas Jay
    Wender, Donald B.
    Faggen, Meredith Gail
    Zemla, Tyler
    Heying, Erica N.
    Schuetz, Samantha R.
    Noble, Stephanie
    Meyerhardt, Jeffrey A.
    Bekaii-Saab, Tanios S.
    Fuchs, Charles S.
    Ng, Kimmie
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [8] Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer
    Janjigian, Yelena Y.
    Ku, Geoffrey Y.
    Campbell, Jenny C.
    Shah, Manish A.
    Capanu, Marinela
    Kelsen, David P.
    Ilson, David H.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (02): : 126 - 130
  • [9] Phase II study of the combination of bevacizumab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma (NB).
    Modak, Shakeel
    Kushner, Brian H.
    Kramer, Kim
    Leyco, Samantha
    Basu, Ellen M.
    Roberts, Stephen S.
    Cheung, Nai-Kong V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
    Musa, Fernanda
    Pothuri, Bhavana
    Blank, Stephanie V.
    Ling, Huichung T.
    Speyer, James L.
    Curtin, John
    Boyd, Leslie
    Li, Xiaochun
    Goldberg, Judith D.
    Muggia, Franco
    Tiersten, Amy
    GYNECOLOGIC ONCOLOGY, 2017, 144 (02) : 279 - 284
12345